ABBVIE BIOTECH VENTURES
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
ABBVIE BIOTECH VENTURES
Industry:
Biotechnology Financial Services Venture Capital
Founded:
2013-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Apache COVID-19 Google Optimize 360 Amazon Elastic Load Balancing Sticky Session Amazon ALB SEO_H2 Adobe Experience Manager
Similar Organizations
BlueStone Venture Partners
BlueStone Venture Partners is a life science venture capital fund investing in entrepreneurial companies.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-01-06 | AmbAgon Therapeutics | AbbVie Biotech Ventures investment in Series A - AmbAgon Therapeutics | 85 M USD |
| 2021-11-02 | Nitrase Therapeutics | AbbVie Biotech Ventures investment in Series A - Nitrase Therapeutics | 7 M USD |
| 2021-10-26 | Quanta Therapeutics | AbbVie Biotech Ventures investment in Series C - Quanta Therapeutics | 60 M USD |
| 2021-08-18 | Jnana Therapeutics | AbbVie Biotech Ventures investment in Series B - Jnana Therapeutics | 50 M USD |
| 2021-08-17 | Starday Foods | AbbVie Biotech Ventures investment in Seed Round - Starday Foods | 4 M USD |
| 2021-07-15 | Stemson Therapeutics | AbbVie Biotech Ventures investment in Series A - Stemson Therapeutics | 15 M USD |
| 2021-06-14 | Ribon Therapeutics | AbbVie Biotech Ventures investment in Series C - Ribon Therapeutics | 65 M USD |
| 2021-03-03 | Caribou Biosciences | AbbVie Biotech Ventures investment in Series C - Caribou Biosciences | 115 M USD |
| 2021-03-01 | Carisma Therapeutics | AbbVie Biotech Ventures investment in Series B - Carisma Therapeutics | 12 M USD |
| 2021-01-07 | Carisma Therapeutics | AbbVie Biotech Ventures investment in Series B - Carisma Therapeutics | 47 M USD |
More informations about "AbbVie Biotech Ventures"
AbbVie Ventures | AbbVie - Pharmaceutical Research
Head of AbbVie Ventures - Cambridge, MA Christian is a trained geneticist, neurobiologist, and biochemist with global big pharma and large biotech experience, and an ever-curious biotech …See details»
Investing to Develop Tomorrow's Cures by Today's Entrepreneurs
To reinforce our reputation as partner of choice, AbbVie Ventures engaged with innovation ecosystems globally to source investment opportunities. Mitokinin: Regular engagement with …See details»
AbbVie Ventures Portfolio | AbbVie - Pharmaceutical Research
Oct 24, 2024 AbbVie Ventures is focused on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics. ... FireCyte is an emerging biotechnology company …See details»
AbbieVie Ventures » LaunchBio event
Mar 28, 2024 Calling all early-stage biotech and novel therapeutics companies! AbbVie Ventures is the strategic venture arm of AbbVie, with the mission to invest in transformational scientific …See details»
AbbVie Biotech Ventures - CB Insights
Jan 8, 2024 AbbVie was an early investor in Alvine along with AbbVie Biotech Ventures, an AbbVie subsidiary dedicated to making early investments in emerging biotech and …See details»
How AbbVie aims to transform lives with early-stage ... - Nature
Fig. 1 | AbbVie Ventures’ focus areas supporting research and development investment. ADC, antibody–drug conjugate; BBB, blood–brain barrier; CAR, chimeric antigen receptor; Th2, T …See details»
AbbVie Ventures investment portfolio - PitchBook
AbbVie Ventures General Information Company Description. Founded in 2009, AbbVie Ventures is the corporate venture arm of AbbVie based in Cambridge, Massachusetts. The firm seeks to …See details»
Abbvie Biotech Ventures - Private Equity List
Abbvie Biotech Ventures. Investor type. CVC. Last fund created. 2013. AUM-Location. United States. $0-1 m. ... We’re AbbVie’s corporate strategic venture capital arm Investing since …See details»
AbbVie Biotech Ventures Venture Capital Profile | VentureDeal
AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional …See details»
AbbVie - Crunchbase Company Profile & Funding
AbbVie is a biopharmaceutical company that develops pharmaceuticals and medical devices. The company provides products and services to therapeutic areas including immunology, oncology, neuroscience, eye care, virology, …See details»
Funding Research & Development with AbbVie Ventures - Excedr
AbbVie Ventures is a corporate venture capital arm of AbbVie Inc. dedicated to funding emerging biotech, life science, and pharmaceutical companies that work on the world’s most pressing …See details»
AbbVie Biotech Innovators Award - UT SpinUp Lab
The Biotech Innovators Award provides one year of free-lab space at SpinUp, funded by AbbVie Canada, and access to core facilities and services, including membership to the SpinUp …See details»
Partner with Us | AbbVie - Pharmaceutical Research & Development
AbbVie Ventures We strategically invest in transformational scientific opportunities to augment our core R&D interests and gain access to next-generation science and proven scientific leaders. …See details»
UT SpinUp Lab | AbbVie and SpinUp Foster Canadian Life Sciences ...
TORONTO, ON, September 26, 2024 – AbbVie (NYSE: ABBV), jointly with the University of Toronto’s SpinUp, today announced the launch of the AbbVie Biotech Innovators Award, a …See details»
AbbVie and U Toronto collaborate to give Canadian biotech …
Oct 1, 2024 The AbbVie Biotech Innovators Award seeks to bridge the gap between research and commercialization, offering a promising platform for Canadian biotech startups. “The …See details»
AbbVie links up with VC firm to map anti-inflammatory companies
Nov 28, 2022 In fact, the company is teaming up with London-based venture fund Deep Science Ventures to create one or more companies targeting this therapy area. AbbVie links up with …See details»
Enthera Pharmaceuticals extends Series A financing, raising a total …
Jan 28, 2021 Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company by both AbbVie Ventures and …See details»
Raven-built Aliada shuttles its potential best-in-class Alzheimer's ...
Oct 28, 2024 Today, AbbVie announced it is acquiring Aliada for $1.4 billion, motivated by the potential for ALIA-1758, Aliada’s lead program, to be the best-in-class for the treatment of …See details»
AbbVie and SpinUp Foster Canadian Life Sciences Innovation with …
Sep 26, 2024 AbbVie is pleased to collaborate with SpinUp, a purpose-built laboratory for chemistry and biological work—or wet lab—incubator at the University of Toronto, to support …See details»
AbbVie and Anima Biotech Announce Collaboration for the …
Jan 10, 2023 - Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology - Anima will receive an upfront …See details»